Vaccination with tumor extracts circumvents the need to identify specific tumor rejection antigens and extends the use of active immunotherapy to the vast majority of cancers, in which specific tumor antigens have not yet been identified. In this study we examined the efficacy of tumor vaccines comp
in vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates
โ Scribed by V. Coulon; A. Ravaud; R. Gaston; MM. Delaunay; J.L. Pariente; D. Verdier; V. Scrivante; N. Gualde
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- French
- Weight
- 230 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## BACKGROUND. Most strategies in cancer immunotherapy are aimed at the induction of a strong cellular immune response against the tumor. Particularly, CD8 + T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors. METHODS. We used a population o
## Background: Several sensitive surveillance tests reportedly have been used to detect occult neuroblastoma (nb) cells in peripheral blood (pb) and bone marrow (bm). they may be useful in monitoring minimal residual tumor cells. the authors report the feasibility and clinical usefulness of a sensi
## BACKGROUND. In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings. METHODS. Phase II subjects received six administrations of aut